Social Progress Index as a Determinant of Healthcare Access and Treatment in Pancreatic Cancer
Current Oncology · 09.06.2026 · 33 (6) · 346
DOI: 10.3390/curroncol33060346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 09.06.2026. Verfasst von Francisco Tustumi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Einstein Hospital Israelita, São Paulo 05652-900, SP, Brazil. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Health Services Accessibility. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Health accessibility is a key determinant of equitable cancer care. In many countries, specialized oncology services are concentrated in urban and socioeconomically advantaged regions, forcing many patients to travel long distances for treatment. Consequently, geographic and social characteristics may be impactful in determining cancer healthcare outcomes.
Objective
The aim of this study was to evaluate the association between the municipal-level Social Progress Index (SPI) and geographic travel burden, stage at diagnosis, treatment, and survival in patients with pancreatic cancer in São Paulo state, Brazil.
Methods
We conducted a population-based study using data from “Fundação Oncocentro” on adults with pancreatic adenocarcinoma (2005–2025). The SPI (0–100 scale), a composite measure of municipal social and environmental development, was the primary exposure. It is structured into 3 dimensions and 12 components: Basic Human Needs (nutrition, medical care, water and sanitation, housing, safety); Foundations of Well-being (education, information access, health, environmental quality); and Opportunity (rights, freedom of choice, social inclusion, higher education). Municipal residence and cancer center locations were geocoded, and travel distance (km) was estimated. Multivariable Cox, logistic, and linear regression models assessed associations between SPI and overall survival, stage IV at diagnosis, surgery, and travel distance.
Results
A total of 13,478 patients were included (mean follow-up 15.1 ± 27.2 months; mean age 62.3 years; 50.4% male). Stage IV disease was frequent (46.3%), and surgery was performed in 33% of cases. Over half of patients (53.2%) traveled more than 10 km for treatment. Increasing SPI was strongly associated with shorter travel distance (β −62.6 km per SPI unit; p < 0.001) and higher odds of surgery (OR 1.04; p < 0.001) and remained independently associated with a higher likelihood of undergoing surgical treatment (adjusted OR 1.04; p < 0.001). The proportion of stage IV disease did not decrease with increasing SPI and was slightly higher in the highest quartile (49.3%). In survival analysis, SPI demonstrated a protective effect in univariate modeling (HR 0.987; p < 0.001), but lost significance in multivariable analysis (p = 0.125). Travel burden was not retained as an independent predictor of survival after adjustment.
Conclusions
Municipal-level SPI was a strong determinant of healthcare access and the likelihood of receiving surgical treatment for pancreatic cancer. Social and geographic vulnerability directly influence care pathways, revealing structural inequities in access to treatment. SPI-based stratification may serve as a practical tool to identify priority regions for transport support and equitable allocation of oncology services.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Health Sciences, Einstein Hospital Israelita, São Paulo 05652-900, SP, Brazil.
- Department of Surgery, Emory University, Atlanta, GA 30322, USA.
ORCID-Profile: Francisco Tustumi, Victória Bulcão Caraciolo, Bianca Aguiar Giacometti Dos Santos, Lucas Cata Preta Stolzemburg, Daniel José Szor, Pedro Luiz Serrano Uson Junior
Zitieren
APA
Tustumi, F., Maegawa, F. A. B., Caraciolo, V. B., Shimoda, G. M., Rufino, I. P. L., Dos Santos, B. A. G., Stolzemburg, L. C. P., Szor, D. J., Araujo, S. E. A., Uson Junior, P. L. S., & Wolosker, N. (2026). Social Progress Index as a Determinant of Healthcare Access and Treatment in Pancreatic Cancer. Current Oncology, 33(6), 346. https://doi.org/10.3390/curroncol33060346
Vancouver
Tustumi F, Maegawa FAB, Caraciolo VB, Shimoda GM, Rufino IPL, Dos Santos BAG, et al. Social Progress Index as a Determinant of Healthcare Access and Treatment in Pancreatic Cancer. Current Oncology. 2026;33(6):346. doi:10.3390/curroncol33060346
BibTeX
@article{Tustumi2026,
author = {Tustumi, Francisco and Maegawa, Felipe Antonio Boff and Caraciolo, Victória Bulcão and Shimoda, Giovanna Mennitti and Rufino, Isabella Paes Leme and Dos Santos, Bianca Aguiar Giacometti and Stolzemburg, Lucas Cata Preta and Szor, Daniel José and Araujo, Sergio Eduardo Alonso and Uson Junior, Pedro Luiz Serrano and Wolosker, Nelson},
title = {Social Progress Index as a Determinant of Healthcare Access and Treatment in Pancreatic Cancer},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {6},
pages = {346},
doi = {10.3390/curroncol33060346}
}
EUVIMED